Glycated Haemoglobin Is Associated With Poorer Cognitive Performance in Patients With Recent-Onset Psychosis.
cognition
cortisol
early psychosis
glucose
glycated haemoglobin
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2020
2020
Historique:
received:
25
02
2020
accepted:
05
05
2020
entrez:
13
6
2020
pubmed:
13
6
2020
medline:
13
6
2020
Statut:
epublish
Résumé
Glucose abnormalities and cognitive alterations are present before the onset of schizophrenia. We aimed to study whether glucose metabolism parameters are associated with cognitive functioning in recent-onset psychosis (ROP) patients while adjusting for hypothalamic-pituitary adrenal (HPA) axis measures. Sixty ROP outpatients and 50 healthy subjects (HS) were studied. Cognitive function was assessed with the MATRICS Consensus Cognitive Battery. Glycated haemoglobin (HbA1 There were no significant differences in HPA axis measures or glucose parameters, with the exception of C-peptide (that was higher in ROP patients), between groups. ROP patients had a lower performance than HS in all cognitive tasks (p < 0.01 for all tasks). Of all glucose metabolism parameters, HbA1c levels were more clearly associated with cognitive impairment in cognitive tasks dealing with executive functions and visual memory in both ROP patients and HS. Multivariate analyses found a significant negative association between HbA1c and cognitive functioning in five cognitive tasks dealing with executive functions, visual memory and attention/vigilance (a ROP diagnosis by HbA1 Our study found that HbA1
Sections du résumé
BACKGROUND
BACKGROUND
Glucose abnormalities and cognitive alterations are present before the onset of schizophrenia. We aimed to study whether glucose metabolism parameters are associated with cognitive functioning in recent-onset psychosis (ROP) patients while adjusting for hypothalamic-pituitary adrenal (HPA) axis measures.
METHODS
METHODS
Sixty ROP outpatients and 50 healthy subjects (HS) were studied. Cognitive function was assessed with the MATRICS Consensus Cognitive Battery. Glycated haemoglobin (HbA1
RESULTS
RESULTS
There were no significant differences in HPA axis measures or glucose parameters, with the exception of C-peptide (that was higher in ROP patients), between groups. ROP patients had a lower performance than HS in all cognitive tasks (p < 0.01 for all tasks). Of all glucose metabolism parameters, HbA1c levels were more clearly associated with cognitive impairment in cognitive tasks dealing with executive functions and visual memory in both ROP patients and HS. Multivariate analyses found a significant negative association between HbA1c and cognitive functioning in five cognitive tasks dealing with executive functions, visual memory and attention/vigilance (a ROP diagnosis by HbA1
CONCLUSIONS
CONCLUSIONS
Our study found that HbA1
Identifiants
pubmed: 32528326
doi: 10.3389/fpsyt.2020.00455
pmc: PMC7262729
doi:
Types de publication
Journal Article
Langues
eng
Pagination
455Informations de copyright
Copyright © 2020 Montalvo, González-Rodríguez, Cabezas, Gutiérrez-Zotes, Solé, Algora, Ortega, Martorell, Sánchez-Gistau, Vilella and Labad.
Références
PLoS One. 2014 Feb 24;9(2):e89428
pubmed: 24586772
Arch Gen Psychiatry. 1984 Nov;41(11):1090-5
pubmed: 6497572
Psychol Med. 2011 Mar;41(3):463-76
pubmed: 20529412
JAMA Psychiatry. 2017 Mar 1;74(3):261-269
pubmed: 28097367
Actas Luso Esp Neurol Psiquiatr Cienc Afines. 1994 Jul-Aug;22(4):171-7
pubmed: 7810373
Diabetes Care. 2018 Dec;41(12):2535-2543
pubmed: 30327356
Clin Psychopharmacol Neurosci. 2018 Feb 28;16(1):7-17
pubmed: 29397662
Neuropharmacology. 2020 May 15;168:107655
pubmed: 31152767
Clin Endocrinol (Oxf). 2005 Dec;63(6):642-9
pubmed: 16343098
Am J Psychiatry. 2010 Jun;167(6):686-93
pubmed: 20360319
Int J Mol Sci. 2017 Mar 30;18(4):
pubmed: 28358316
Compr Psychiatry. 2015 Nov;63:1-9
pubmed: 26555485
Psychoneuroendocrinology. 2019 Apr;102:24-36
pubmed: 30503781
Curr Med Chem. 2020;27(19):3151-3167
pubmed: 30727866
J Nerv Ment Dis. 1990 Aug;178(8):510-7
pubmed: 2380697
Clin Schizophr Relat Psychoses. 2014 Jan;7(4):223-30
pubmed: 23428789
Psychoneuroendocrinology. 2003 Oct;28(7):916-31
pubmed: 12892658
Schizophr Res. 2019 Aug;210:73-80
pubmed: 31262574
Alzheimer Dis Assoc Disord. 2017 Jan-Mar;31(1):48-54
pubmed: 28225507
J Clin Endocrinol Metab. 2001 Jan;86(1):245-50
pubmed: 11232008
Mol Psychiatry. 2019 Aug 29;:
pubmed: 31467393
Psychoneuroendocrinology. 2019 Feb;100:203-212
pubmed: 30388594
Psychoneuroendocrinology. 2014 Aug;46:1-13
pubmed: 24882153
J Mol Neurosci. 2017 May;62(1):88-98
pubmed: 28378260
J Psychosom Res. 2020 May;132:109968
pubmed: 32169752
Rev Psiquiatr Salud Ment. 2018 Apr - Jun;11(2):115-124
pubmed: 28993125
Diabetes Care. 1999 Sep;22(9):1450-7
pubmed: 10480508
Psychiatry Res. 2015 Oct 30;229(3):901-4
pubmed: 26279127
Schizophr Res Cogn. 2015 Dec 17;2(4):172-178
pubmed: 29114461
Am J Psychiatry. 2008 Feb;165(2):203-13
pubmed: 18172019
Curr Neuropharmacol. 2014 May;12(3):273-80
pubmed: 24851091
Aust N Z J Psychiatry. 2018 Jun;52(6):585-595
pubmed: 29232966
Schizophr Res. 2008 Jan;98(1-3):302-6
pubmed: 18031995
JAMA Psychiatry. 2014 Oct;71(10):1121-8
pubmed: 25133871
Schizophr Res. 2015 Aug;166(1-3):37-42
pubmed: 25982813
Am J Psychiatry. 2017 Jul 1;174(7):686-694
pubmed: 28103712
Psychiatry Res. 1999 Oct 18;88(1):1-13
pubmed: 10641582
Physiol Rev. 2016 Oct;96(4):1169-209
pubmed: 27489306
Diabetes Care. 1987 Sep-Oct;10(5):662-4
pubmed: 3677988
Am J Psychiatry. 2015 Apr;172(4):323-34
pubmed: 25698435
Curr Psychiatry Rep. 2008 Apr;10(2):164-70
pubmed: 18474210
Arch Gerontol Geriatr. 2016 Jan-Feb;62:138-42
pubmed: 26381432
Br J Psychiatry. 2009 May;194(5):434-8
pubmed: 19407273
Schizophr Res. 2016 Mar;171(1-3):182-6
pubmed: 26805411
Diabetes Care. 2010 Apr;33(4):714-20
pubmed: 20097784
Pharmacol Res. 2016 Jul;109:74-80
pubmed: 26748034
Neurosci Biobehav Rev. 2011 Jan;35(3):573-88
pubmed: 20620163
Psychol Med. 2016 Nov;46(15):3219-3230
pubmed: 27604840
Am J Psychiatry. 2003 Feb;160(2):284-9
pubmed: 12562574
Med Hypotheses. 2015 Oct;85(4):391-6
pubmed: 26118462
Neuropharmacology. 2011 Dec;61(7):1123-8
pubmed: 21420985
J Clin Epidemiol. 2001 Apr;54(4):343-9
pubmed: 11297884
Arch Gen Psychiatry. 1984 Nov;41(11):1086-9
pubmed: 6497571
Rev Neurosci. 2017 Oct 26;28(7):715-723
pubmed: 28704200
Psychol Med. 2017 Apr;47(6):1030-1040
pubmed: 28032535
Psychoneuroendocrinology. 2013 Jun;38(6):941-6
pubmed: 23063878
Arch Gen Psychiatry. 2012 Jun;69(6):562-71
pubmed: 22664547
Obes Rev. 2012 Oct;13(10):923-84
pubmed: 22780564
Stress. 2016 Jul;19(4):383-9
pubmed: 27320489
Arch Gen Psychiatry. 1990 Jun;47(6):589-93
pubmed: 2190539
Psychoneuroendocrinology. 2014 Mar;41:23-32
pubmed: 24495605
Schizophr Bull. 2013 Nov;39(6):1174-9
pubmed: 24072812
J Chem Neuroanat. 2017 Oct;83-84:59-68
pubmed: 27480675
JAMA Psychiatry. 2016 Mar;73(3):247-59
pubmed: 26792761
Psychoneuroendocrinology. 2016 Oct;72:54-62
pubmed: 27344379
Psychoneuroendocrinology. 2016 Jan;63:414-32
pubmed: 26563991
Lancet Diabetes Endocrinol. 2015 Jan;3(1):75-89
pubmed: 25163604
Psychol Med. 2016 Jul;46(10):2133-44
pubmed: 27055381